Impact News +++ ANLEIHEN-Woche #KW34 – 2025: Energiekontor, JDC, The Platform Group, Aream, LEEF, Dt. Rohstoff,... (Anleihen-Finder) +++ PLATFORM GROUP Aktie +4,84%

CITIUS PHARMACEUTICALS Aktie

>CITIUS PHARMA Performance

1 Woche: 0%

1 Monat: -72,0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>CITIUS PHARMACEUTICALS Aktie

Name:

CITIUS PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US17322U3068 / A40MD0

Symbol/ Ticker:

47N0 (Frankfurt) / CTXR (NASDAQ)

Kürzel:

FRA:47N0, ETR:47N0, 47N0:GR, NASDAQ:CTXR

Index:

Webseite:

https://www.citiuspharma...

Profil:

Marktkapitalisierung:

17.88 Mio. EUR

Unternehmenswert:

16.42 Mio. EUR

Umsatz:

EBITDA:

-35.13 Mio. EUR

Nettogewinn:

-34.55 Mio. EUR

Gewinn je Aktie:

-4.26 EUR

Schulden:

1.61 Mio. EUR

Liquide Mittel:

5.23 Mio. EUR

Operativer Cashflow:

-17.67 Mio. EUR

Bargeldquote:

0.12

Umsatzwachstum:

Gewinnwachstum:

-5.15%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CITIUS PHARMACEUTICALS, CITIUS PHARMA, CITIUS PHARMACEUTICAL

Letzte Datenerhebung:

22.08.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 17.01 Mio. St.

Frei handelbar: 94.26%

Leerverk. Aktien: 8.95%

Rückkaufquote: -79.22%

Mitarbeiter: 23

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 389.8%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 0.27

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -35.83%

Eigenkaprendite: -53.42%

>Peer Group

Es sind 601 Aktien bekannt.

>CITIUS PHARMA Chart & Kurs - NASDAQ

>CITIUS PHARMA News

12.08.25 - 22:48	Citius Pharmaceuticals GAAP EPS of -$0.08 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 22:33	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J., Aug. 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals,......

12.08.25 - 22:33	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	LYMPHIR commercial availability planned for the fourth quarter of 2025 $12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive......

17.07.25 - 22:33	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire)
	CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182......

16.07.25 - 15:18	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire)
	CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182......

08.07.25 - 14:54	Citius Pharmaceuticals regains Nasdaq compliance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.07.25 - 14:36	Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
	CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that for 10 consecutive trading days, from June 20,......

17.06.25 - 14:09	Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 (PR Newswire)
	CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an......

12.06.25 - 14:36	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
	$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J., June 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical......

10.06.25 - 13:45	Citius Pharmaceuticals announces registered direct offering of $15.8 million (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.06.25 - 13:09	Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
	$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J., June 10, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical......

09.06.25 - 15:42	Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR (AFX)
	WASHINGTON (dpa-AFX) - Citius Oncology, Inc. (CTOR), the oncology-focused subsidiary of late-stage biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR), announced Monday it has entered in......

09.06.25 - 14:39	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire)
	Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")......

14.05.25 - 23:00	Citius Pharmaceuticals GAAP EPS of -$0.11 beats by $0.27 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:33	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial......

05.05.25 - 14:39	Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (PR Newswire)
	CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur, Chairman and Chief Executive......

01.04.25 - 15:15	Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.03.25 - 22:33	The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology \| DelveInsight (PR Newswire)
	With the emergence of novel therapies and expanded indications, the United States IL-2 market is projected to reach USD 4 billion by 2034. Key players driving this expansion include Iovance Biotherapeutics, Eisai, Citius Pharmaceuticals, Nektar Therapeutics, Mural Oncology, Corvus......

26.11.24 - 08:03	XFRA : INSTRUMENT_SUSPENSION - US17322U3068 (XETRA)
	Instrument ID [21765584] (47N0 - US17322U3068) suspended...

26.11.24 - 08:03	XFRA : 47N0: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CITIUS PHARMAC. DL -,001 47N0 US17322U3068 BAW/UFN...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das nackte Kind, das zagt nicht; mit seinem Pfennig springt es fort und kennt recht gut den Sammelort - ich meine des Bäckers Laden. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram